NASDAQ:ICLR - Icon Stock Price, Forecast & News

Icon trades on the NASDAQ under the ticker symbol "ICLR."

Icon Plc (NASDAQ:ICLR) announced its quarterly earnings results on Wednesday, October, 23rd. The medical research company reported $1.74 earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of $1.74. The medical research company had revenue of $710.40 million for the quarter, compared to the consensus estimate of $709.75 million. Icon had a net margin of 13.16% and a return on equity of 24.86%. The firm's quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.54 earnings per share. View Icon's Earnings History.

Icon is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for Icon.

Icon will be holding an earnings conference call on Wednesday, February 19th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Icon issued an update on its FY20 earnings guidance on Tuesday, January, 14th. The company provided earnings per share (EPS) guidance of $7.55-7.85 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.71. The company issued revenue guidance of $2.97-3.09 billion, compared to the consensus revenue estimate of $3.03 billion.

9 brokers have issued 1-year target prices for Icon's stock. Their forecasts range from $154.00 to $185.00. On average, they expect Icon's stock price to reach $166.88 in the next twelve months. This suggests that the stock has a possible downside of 4.5%. View Analyst Price Targets for Icon.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.

News stories about ICLR stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Icon earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Icon.

Icon saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,180,000 shares, an increase of 16.8% from the December 15th total of 1,010,000 shares. Based on an average daily trading volume, of 261,500 shares, the short-interest ratio is currently 4.5 days. Currently, 2.2% of the company's shares are short sold. View Icon's Current Options Chain.

Some companies that are related to Icon include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), PRA Health Sciences (PRAH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Icon investors own include Pfizer (PFE), Gilead Sciences (GILD), CVS Health (CVS), Mastercard (MA), Procter & Gamble (PG), Post (POST), Visa (V), Johnson & Johnson (JNJ), Exxon Mobil (XOM) and Amgen (AMGN).

Icon's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.42%), Summit Creek Advisors LLC (0.27%), Mckinley Capital Management LLC Delaware (0.19%), LVM Capital Management Ltd. MI (0.12%), Farmers & Merchants Investments Inc. (0.07%) and Henry James International Management Inc. (0.06%).

ICLR stock was sold by a variety of institutional investors in the last quarter, including Farmers & Merchants Investments Inc., Peregrine Capital Management LLC, RBA Wealth Management LLC, Arden Trust Co, Summit Creek Advisors LLC, Groesbeck Investment Management Corp NJ, Welch & Forbes LLC and Tealwood Asset Management Inc..

ICLR stock was bought by a variety of institutional investors in the last quarter, including State of Michigan Retirement System, Zurcher Kantonalbank Zurich Cantonalbank , Mckinley Capital Management LLC Delaware, Diversified Trust Co, First National Bank of Omaha, Henry James International Management Inc., We Are One Seven LLC and Harbour Capital Advisors LLC.

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ICLR stock can currently be purchased for approximately $174.79.

Icon has a market capitalization of $9.43 billion and generates $2.60 billion in revenue each year. The medical research company earns $322.66 million in net income (profit) each year or $6.29 on an earnings per share basis. Icon employs 13,670 workers across the globe.View Additional Information About Icon.

The official website for Icon is http://www.iconplc.com/.

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.